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Abstract
Background: Small non-coding RNAs play essential roles in gene regulation, however, the interplay between RNA
groups, their expression levels and deregulations in tumorigenesis requires additional exploration. In particular, a
comprehensive analysis of microRNA (miRNA), PIWI-interacting RNAs (piRNAs), and tRNA-derived small RNAs in
human testis and testicular germ cell tumor (TGCT) is lacking.
Results: We performed small RNA sequencing on 22 human TGCT samples from 5 histological subtypes, 3 carcinoma
in situ, and 12 normal testis samples. miRNA was the most common group among the sequences 18–24 nt in length
and showed histology-specific expression. In normal samples, most sequences 25–31 nucleotides in length displayed
piRNA characteristics, whereas a large proportion of the sequences 32–36 nt length was derived from tRNAs.
Expression analyses of the piRNA population demonstrated global loss in all TGCT subtypes compared to normal testis.
In addition, three 5′ small tRNA fragments and 23 miRNAs showed significant (p < 10−6) differential expression in cancer
vs normal samples.
Conclusions: We have documented significant changes in the small RNA populations in normal adult testicular
tissue and TGCT samples. Although components of the same pathways might be involved in miRNA, piRNA and
tRNA-derived small RNA biogenesis, our results showed that the response to the carcinogenic process differs
between these pathways, suggesting independent regulation of their biogenesis. Overall, the small RNA
deregulation in TGCT provides new insight into the small RNA interplay.
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Background
In recent years, it has become increasingly evident that
many non-protein-coding regions of the genome are
transcribed [1], giving rise to non-coding RNAs (ncRNA)
that play crucial roles in normal biological processes and
human diseases [2]. Within the diverse group of ncRNA,
small non-coding RNAs (sncRNAs) have emerged as po-
tential important regulators of gene expression [3]. These
RNA molecules are highly complex in terms of structural
diversity and function. They are typically 19–35 nucleo-
tides (nt) in length, interact with Argonaute family pro-
teins [4–7], and include microRNAs (miRNAs), and
PIWI-interacting RNAs (piRNAs). Precise control of
miRNA expression is crucial for keeping cells in normal
physiological states, and dysregulation of miRNAs may
lead to oncogenesis [8, 9]. The miRNA pathway is
thought to be important for spermatogenesis [10] and
several miRNAs have been found to be exclusively or
preferentially expressed in the testis [11]. Moreover, the
miRNAs miR-371-373, miR-302 and miR-146 have previ-
ously been shown to display a TGCT-specific expression
pattern [12–14], indicating a potential role for miRNAs in
TGCT pathogenesis.
Unlike miRNA expression, piRNAs are mainly restricted
to the male germline [5, 15–17], but have recently also
been found in small amounts in somatic tissues, including
cancer [18–21]. It has been reported that piRNAs tend to
be generated in a clustered fashion from specific loci in
the genome [5, 16], and that they are mainly transcribed
from regions containing transposons and other repetitive
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elements [2, 22]. They are generated from long primary
transcripts that are processed by unknown endonucleases
into mature piRNAs [22, 23]. Their roles in humans are
still unclear, but studies in model organisms suggest a role
in transposable element regulation and DNA methylation
[23–28]. It is thought that they form piRISC complexes
with PIWI proteins and target mRNAs for cleavage or
translational repression by binding to complementary se-
quences in target mRNAs [29, 30].
Other classes of sncRNAs have also been identified, in-
cluding tRNA-derived small RNAs, a class of small RNA
generated by specific endonucleases from mature tRNAs
in response to certain conditions, such as oxidative
stress, heat shock, or nutrient deprivation [31–33]. Pre-
vious studies have shown that tRNA-derived small RNAs
can be divided into two main groups; small tRNA frag-
ments (tRFs) (~20 nt in length) and tRNA halves
(~30 nt in length) [32]. Their mode of action is still un-
clear, but they may influence cell proliferation, probably
through translational arrest [32, 33]. Yamasaki and co-
workers showed that stress induction in mammalian
cells leads to formation of tRNA halves that inhibit
translation [33]. This inhibitory effect is specific for se-
quences derived from the 5′ end of mature tRNAs [34].
Recently, Keam and co-workers showed that HIWI2, a
human PIWI homolog, binds 5′ tRNA-derived small
RNAs in a human breast cancer cell line, indicating
crosstalk between the piRNA and tRNA pathways [20].
Similar tRNA-derived small RNAs have also been de-
tected in all stages of mouse spermatogenesis [35].
Small ncRNA may play an important role in TGCT.
TGCT develops from carcinoma in situ (CIS; alias intra-
tubular germ cell neoplasia) lesions that may arise in
utero from primordial germ cells (PGCs) [36] and is the
most common malignancy in young men in most west-
ern countries [37, 38]. The etiology of TGCT is largely
unknown, although genetic components and conditions
during pregnancy play a role [39–41]. In CIS cells, the
demethylation machinery maintains the genome in a
generally demethylated state, much like in undifferenti-
ated PGCs [42], indicating an epigenetic component in
the development of testicular neoplasia. Recently, down-
regulation of the PIWI-piRNA pathway in human
TGCTs was shown by Ferreira and coworkers [43].
Downregulation was associated with loss of LINE-1
methylation. Combined, these findings indicate that epi-
genetic disruption is a hallmark for the development of
testicular tumors, and that it is affected by the sncRNA
expression.
Despite the emerging biological significance of sncRNAs,
most studies thus far have been conducted in model organ-
isms. Therefore, the abundance, diversity, origin, and func-
tion of human sncRNAs are still relatively unknown.
Although several studies have been performed on the role
of miRNAs in spermatogenesis and TGCT, little is known
about the presence and molecular function of other classes
of human testicular sncRNAs. This exploratory study eluci-
dates the presence and expression levels of small RNA
populations in normal testicular tissue and TGCT histo-
logical subtypes. We analyzed the distribution of sncRNAs
Table 1 Data processing metrics for small RNA reads
Histology No of
samples
Sequences Aligned Unique aligned Assigned to
miRNAd
Assigned to small RNA
contigs





































Chorio-carcinoma 1 80,68,838 6,171,431 (76.5 %) 4,171,369 (51.7 %) 4,545,330 8,955,051





Raw sequence data from the small RNA sequencing dataset. Percentage >100 % is due to multiple hits in the sequence mapping. aThe normal samples are from
11 healthy men and 1 biopsy from histological normal tissue adjacent to a tumor in a TGCT patient. b The cell line samples consists of cells from the embryonal
carcinoma lines NT2 and 2102Ep. c Evaluation of cryosections of the carcinoma in situ samples estimated presence of CIS cells in 10 %, 50 %, and 100 % of the
seminiferous tubuli. d As annotated by miRBase
Rounge et al. Molecular Cancer  (2015) 14:153 Page 2 of 13
across the human genome by small RNA sequencing on
RNA isolated from a total of 37 human samples.
Results
The small RNA populations differ between normal and
TGCT tissue
The resulting small RNA dataset encompasses samples
from all major histological TGCT subtypes and relevant
cell lines, and yielded almost 379 million sequence reads
(Table 1). The lowest average sequence count came from
the EC-cell lines, and the highest from CIS samples.
After sequence trimming, 76.5 % of the sequences
mapped to the reference genome, of which 63.7 %
mapped uniquely. In consistence with the piRNA signa-
ture observed in previous studies [5, 16, 25], a propor-
tion of the putative piRNA sequences in each sample
group mapped to several loci in the genome.
The small RNA length distribution shows abundant
sequences in the size range 19 to 36 nt (Fig. 1a). The
length distribution for the normal samples shows three
peaks centered at 22, 30 and 33 nt. The length of the se-
quences in the two former peaks is consistent with the
presence of miRNAs and piRNAs, respectively [17, 44].
The piRNA peak is lower in the TGCT samples com-
pared to the normal samples, demonstrating a difference
in the small RNA populations in normal and TGCT
samples. Sequence conservation at each position differs
between TGCT, CIS and normal samples. Consistent
with the presence of piRNAs, nearly 70 % of the se-
quences from normal samples 24–30 nt in length con-
tain uridine in the 5′ position (5′U; Fig. 1b-c), and we
also observe a slightly elevated proportion of sequences
containing adenine in the 10th position (10A). The pro-
portion of 5′U and 10A show a strong decrease from 30
to 33 nt sequence length. The CIS subtype has a base
composition pattern that resembles that of the normal
samples, whereas the TGCT samples display a random
distribution of the nucleotides in position 1 and 10
(probability for each base close to 25 %) (Fig. 1b-c). Add-
itionally, sequences 32–34 nt in length in all sample
groups show a significant enrichment for 5′G, corre-
sponding to the decrease in sequences containing 5′U
(Fig. 1c). The cancer sequences >30 nt in length contain
a large proportion of similar sequences (data not
shown), resulting in the appearance of a AGUGGUU
motif in positions 14–20 (Fig. 1c).
The sequences were assigned to different classes based
on annotations of the mapped region and the sequence
lengths corresponding to the three peaks observed in
the length distribution plot. The aligned sequences make
up between 58.8 – 81.1 % of all sequences (Table 1). A
large proportion of the sequences 18–24 nt were anno-
tated as miRNAs (Fig. 2a), whereas around 30 % of the se-
quences were derived from exons. The distribution of
annotated sequences was similar for all histological sub-
groups. Sequences 25–31 nt in length, however, vary with
sample groups (Fig. 2b and Additional file 1). In particular,
60.0 % of the normal sequences were derived from re-
peats, whereas repeat-associated sequences constitute 9.6
– 41.8 % of the sequences in the TGCT samples.
The absolute difference in sequence counts between
normal and TGCT samples in this size range are mostly
due to low abundance of repeat-associated sequences in
the TGCT samples (on average 10.5 and 4.2 mill se-
quences, respectively, not including the CIS samples)
(Additional file 1). This reduction is in accordance with
loss of the 30 nt peak observed in the TGCT sequence
length distribution plot (Fig. 1a). In addition, a large pro-
portion of the TGCT sequences 25–31 nt in length are
derived from tRNAs. This tRNA enrichment was even
more pronounced in sequences 32–36 nt in length,
Table 2 Top 10 differentially expressed piRNA clusters (A),
tRNA-derived small RNAs (B) and miRNAs (C)
A Top 10 differentially expressed small RNA clusters
Genomic location Log2 Fold Change P-value (adjusted)
1 chr15:21,925,462-21,930,432 −6.18 2.62e-29
2 chr15:20,841,664-20,850,393 −6.18 1.31e-27
3 chr15:23,510,099-23,514,854 −6.25 1.46e-26
4 chr18:55,837,529-55,838,674 inf 1.46e-26
5 chr1:2,237,998-2,241,778 −6.55 1.88e-26
6 chr15:23,386,898-23,404,357 −6.06 1.88e-26
7 chr15:28,583,287-28,593,483 −5.93 1.88e-26
8 chr4:190,801,280-190,804,618 −6.21 1.88e-26
9 chr15:20,723,798-20,737,584 −5.94 3.27e-26
10 chr18:14,460,205-14,464,963 −6.30 3.27e-26
B Differentially expressed tRNA-derived small RNAs
tRNA Log2 Fold Change P-value (adjusted)
1 Glu-GAG (chr13, 45492060) −2.51 2.50e-09
2 Glu-GAG (chr15, 26327380) −2.63 2.50e-09
3 Asp-GAY (chrX, 18996334) −3.49 3.40e-06
C Top 10 differentially expressed miRNAs
miRNA Log2 Fold Change p-value (adjusted)
1 hsa-miR-302d-3p 11.25 1.95e-13
2 hsa-miR-302a-3p 11.65 1.23e-12
3 hsa-mir-302b 11.38 1.23e-12
4 hsa-mir-302a 11.18 7.26e-12
5 hsa-miR-367-3p 10.20 1.48e-11
6 hsa-miR-371a-5p 9.29 2.09e-11
7 hsa-miR-371b-3p 9.29 2.09e-11
8 hsa-miR-302c-5p Inf 3.45e-11
9 hsa-miR-302d-5p Inf 1.38e-10
10 hsa-miR-302c-3p 11.32 1.38e-10
Rounge et al. Molecular Cancer  (2015) 14:153 Page 3 of 13
where ~90 % of the sequences in all sample groups were
tRNA-derived (Fig. 2c). The CIS samples have a se-
quence annotation distribution intermediate between
normal testis and TGCT samples.
The piRNA biogenesis pathway is globally downregulated
in TGCT samples
Mature piRNAs originate from processing of longer
RNA precursors [45]. We merged direction-specific
Fig. 1 Small RNA length distribution and base compositions in normal and TGCT samples. a Small RNA sequence length distribution in each
sample group (sequences 18–36 nt in length) based on normalized counts in each sample. b The percentage of reads aligning to the human
genome with U in first position, G in first position, and A in 10th position for unique small RNA sequences 24–36 nt in length in each sample
group. The horizontal line at 25 % in the plots represents the expected base proportion under random distribution. C Web logos for unique,
trimmed sequences 30 and 33 nt in length showing the base composition in each nucleotide position. The X-axis represents the nucleotide
position relative to the 5′ end, whereas the Y-axis represents the entropy score for the base bias
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overlapping small RNA sequences into contigs allowing
gaps up to 100 bp, mimicking piRNA precursors. Se-
quences 24 to 35 nt in length were included to be able
to study both putative piRNAs and tRNA-derived se-
quences. A total of 184,344 small RNA contigs were
generated, with a mean and median length of 516 and
188 bases, respectively.
Differential expression analysis of contigs from normal
testis and TGCT samples (including CIS samples) re-
vealed a genome-wide loss of small RNA contigs in the
TGCT samples (Fig. 3a). This loss leads to the asymmet-
ric, left-skewed shape of the volcano-plot observed in
Fig. 3b, revealing an average log2 fold change of −5. The
most differentially expressed small RNA contigs are
listed in Table 2A, all of which are down-regulated in
TGCT. The 5′U preference in the sequences 25–31 nt
in length indicate that these sequences are mainly piR-
NAs. piRNABank consists of 667,666 piRNA sequences
and 114 high density regions, called piRNA clusters [46].
All piRNABank clusters and 20 % (131,176) of the se-
quences overlap with the small RNA contigs in our dataset.
47 % (86,240) of the 184,344 small RNA contigs overlap
with piRNABank sequences. Differential expression ana-
lyses of sequences overlapping with piRNA bank sequences
show the same expression pattern as the small RNA con-
tigs, although with lower counts (Additional file 5). A table
indicating the top 10 differentially expressed piRNAs when
including sequences overlapping with piRNABank only, is
given in Additional file 6. Hierarchical clustering showed
that normal testis samples and TGCT samples clustered
separately, but with no sub-clustering related to TGCT
histological subtypes (Fig. 3a).
Despite the global downregulation of small RNA contigs
in TGCT, a subset of the contigs was expressed in all sam-
ples. Further analysis showed that these sequences are
mainly tRNA-derived. We therefore identified all se-
quences overlapping with known tRNA genes and per-
formed differential expression analyses for tRNA halves
and tRFs, based on sequence length. No sequences corre-
sponding to tRNA halves showed significant expression be-
tween TGCT and normal testis (p > 10−4; data not shown).
Differential expression analyses of the tRNA-associated se-
quences ~20 nt in length (tRFs) indicated a significant dif-
ference in the sequences derived from three tRNA genes,
all downregulated in TGCT (p < 10−6, Table 2B).
Hierarchical clustering based on data from tRNA
halves and tRFs did not group the samples according to
histology (Additional file 2A-B). However, sequences de-
rived from tRNAs of the same isotype cluster together,
as apparent by the horizontal groups in the heatmaps
(Additional file 2A-B). This can also be seen in the cor-
responding volcano-plots, which display a similar distri-
bution of the sequences in the TGCT and normal testis
samples (Additional file 2C-D). Most tRNA isotypes are
represented, but tRNAs encoding the amino acids Val,
Gly, Glu and Lys are overrepresented in the 100 most
highly expressed sequences in both groups. The expres-
sion of corresponding tRNA halves and tRFs correlate
(log scale), however, a few tRNAs (tRNA-Val-GTG/GTY,
tRNA-Gly-GGY/GGG) have a higher abundance in tRFs
compared to tRNA halves (Additional file 3A-B). The
tRNA-derived sequences are mostly derived from the 5′
end of mature tRNAs (representative example of reads



























































































































































































Sequences 25-31 nt in length
Fig. 2 Relative distribution of small RNA sequences in three classes according to annotation. The sequences are divided into three categories
based on the peaks in the size distribution, corresponding to miRNAs, piRNAs and longer sequences of previously unknown origin. The
histograms indicate the average sequence count per sample in each group. * As annotated by miRBase, ** As annotated by piRNABank
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Expression analysis of miRNAs shows upregulation of the
miR-302 and miR-371-373 clusters
To assess the miRNA population in our samples, se-
quences with lengths corresponding to miRNAs (17–23 nt
in length) were analyzed. A total of 23 miRNAs show dif-
ferential expression between normal testis and TGCT
samples (p < 10−6). The top 10 most differentially
expressed miRNAs are listed in Table 2C, and an extended
list containing all 23 significant miRNAs is given in Add-
itional file 4.
The miRNA expression profiles reflect TGCT histo-
logical subtypes. Hierarchical clustering generated a den-
drogram aligning with the experimental factors (cases
and controls) and TGCT histological subtypes (Fig. 4a).
The CIS samples cluster closely together with the nor-
mal samples, further verifying our observations that CIS
represents an intermediate stage between normal and
malignant testicular tissue.
In contrast to the results on small RNA contig expres-
sion, the volcano plot for the miRNA data generates a
symmetrical pattern, indicating that some miRNAs are
downregulated, whereas others are upregulated in
TGCT (Fig. 4b). The most significantly differentially
expressed miRNAs were from the miRNA clusters miR-
302/367 and miR-371-373, seen in the upper right corner
of the plot.
We selected three miRNAs, piRNAs and tRFs for val-
idation using qPCR. The validation shows corresponding
up/downregulation to the small RNA sequencing (Fig. 5),
although intra-group variation is observed.
Discussion
During the last decade, several novel classes of sncRNAs
have been identified. These molecules are highly com-
plex, and their biogenesis, molecular function and regu-
lation are still largely unknown [47]. With this study we
provide, to our knowledge, the first comprehensive
characterization of the small RNA sequences in different
histological subtypes of TGCT, and testicular carcinoma
in situ, as well as in normal testis samples. Overall, we
show that the human testis is highly abundant in miR-
NAs, piRNAs and tRNA-derived small RNAs. More spe-
cifically, the small RNA population in our dataset
showed characteristics of canonical piRNAs, with an
overall genomic distribution closely resembling that of a
previous study [5], as well as a large overlap with piR-
NABank [46]. In addition, we confirm the findings from
other studies showing that human piRNAs, like piRNAs
in other organisms, have a strong preference for 5′ U
[25, 48–50]. Together, these results strongly imply that a
large proportion of the small RNAs, are indeed piRNAs.
In the normal samples, we also observed a slightly ele-
vated proportion of 10A in sequences 24–30 nt in
length, indicating that some piRNAs may be generated
through the ping-pong mechanism [25, 48, 49].
Most piRNAs are globally downregulated or com-
pletely lost in all TGCT histological subtypes. This is
not surprising, as tumor tissue has fewer differentiated
Fig. 3 Small RNA contig expression in normal and TGCT samples. a
Heatmap showing the expression data of the 2000 most highly
expressed piRNAs (variance stabilization transformed data). The
dendrogram (bottom) indicates clustering according to expression
profiles. Heatmap colors represent relative small RNA contig
expression as indicated in the color key (bottom right). b Volcano
plot indicating the relationship between the Log2 fold change and
p-values (Benjamini-Hochberg adjusted) for all small RNA contigs
when comparing TGCT with normal samples. The CIS samples are
included in the TGCT group. Color coding indicates the expression
level as a function of normalized counts (BaseMean)
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Fig. 4 miRNA expression in normal and TGCT samples. a Heatmap showing the expression data of the 100 most highly expressed miRNAs
(variance stabilization transformed data). The dendrogram (bottom) indicates clustering according to expression profiles. Heatmap colors
represent relative miRNA expression as indicated in the color key (bottom right). b Volcano plot indicating the relationship between the Log2
fold change and p-values (Benjamini-Hochberg adjusted) for all miRNAs when comparing TGCT with normal samples. The CIS samples are included in
the TGCT group. Red color coding indicates a significance level of p < 10−8 on a –log10 scale and log2 fold change above 5/below −5
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germ cells, the main producer of piRNAs [5, 15–17] com-
pared to normal testis. Global downregulation of piRNAs
in TGCT is supported by the findings of Ferreira and co-
workers, describing diminished levels of PIWI proteins
and piRNAs both in TGCT primary tumors and cultured
transformed cells [43]. Among the TGCT samples, we
found 1) no histology-specific piRNA profiles, 2) no en-
richment for 5′U and 10A, and 3) a lower read count for
sequences 24–30 nt in length. Combined, these data indi-
cate a lack of sequences generated through the piRNA
pathway in TGCT. Some piRNAs are, however, detected
in the cancer samples, shown by both the small RNA se-
quencing and qPCR validation, probably originating from
a few normal cells within the tumors/biopsies.
TGCT develops from CIS lesions that may arise in
utero in PGCs or gonocytes [36]. Although PGCs or
gonocytes are not present in normal testis, we have con-
sidered CIS to represent a transitional state between
normal testis tissue and TGCT, evident by the
intermediate levels of 5′ U/10A enrichments observed
in CIS samples (Fig.1b). Only a proportion of the tubular
cells will be affected in CIS (5-10 % abnormal cells [51]
in a 100 % CIS sample), generating a mix of normal sper-
matogenic and neoplastic cells. Almstrup and co-workers
have previously determined the three CIS samples in-
cluded in our study to contain 10 %, 50 %, and 100 % af-
fected seminiferous tubuli, respectively [51]. The samples
do not cluster together in the piRNA dendrogram (Fig. 3a),
probably due to the differences in the amount of neoplas-
tic cells within the samples. Interestingly, the sample con-
taining the highest amount of affected tubules cluster
together with an embryonic carcinoma (EC) sample,
whereas the sample containing the lowest amount of af-
fected tubules clusters together with the healthy controls.
The high abundance of tRNA-derived RNAs 32–36 nt
in length, representing tRNA halves, is in accordance
with other studies [20, 35]. Differential expression ana-























































































































































































































































Fig. 5 qPCR validation. Three small non-coding RNA sequences in each of the three categories miRNA (blue), piRNA (red) and tRF (green) were
selected and their relative expression in 8 samples (4 normal, 4 cancer) was analyzed using qPCR. The first normal sample is used as reference (RQ = 1).
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their high abundance, no tRNA halves are differentially
expressed between TGCTand normal tissue. This indicates
that the population of tRNA halves is not affected by
tumorigenesis. Most tRNA halves were found to be derived
from the 5′ end of mature tRNA [20, 35], suggesting that
they are not degradation products, but rather processed
tRNAs. The overrepresentation of only a few tRNAs, is
similar to the results in other studies [20, 35].
In addition to tRNA halves, we identified tRNA-
derived sequences ~20 nt in length, corresponding to
tRNA Fragments (tRFs) [47]. These tRFs may be pro-
duced from the 5′- or 3′-end of mature tRNAs by Dicer,
and associate with AGO proteins to participate in vari-
ous processes of transcriptional and post-transcriptional
regulation [52–54]. Not much is known about the role
of tRNA-derived small RNAs in cancer. It it has been re-
ported that the levels of mature tRNAs are generally ele-
vated in cancer [55], whereas our results indicate that
the levels of tRNA halves and tRFs are relatively stable
in TGCT. The findings by Keam et al., showing that
tRNA-derived small RNAs bind to HIWI2 [20], indicate
crosstalk between sncRNA pathways and may indicate
that the sncRNA classes are more overlapping in terms
of function and biogenesis than previously thought. Our
results, however, show that the response to the carcino-
genic process differs between these pathways, suggesting
independent regulation of their biogenesis. More re-
search is needed to elucidate the potential targets of
tRNA-derived small RNAs and their role in cancer, in-
cluding in TGCT.
Whereas piRNAs are almost exclusively found in the
male gonad [5, 16, 17], miRNAs are expressed in most
cell types. The miRNA population varies, however
between tissues. We speculate that the observed
differences in miRNA profiles are driven by differences
in the cellular origins of the TGCT subtypes, whereas
piRNAs are lost in the carcinogenic cells due to the
spermatogenesis-specific expression of this pathway. This
lack of piRNA defense in CIS and TGCT cells may be a
factor in testicular carcinogenesis, causing reduced ability
to prevent chromatin instability. Diminished piRNA ex-
pression and hypomethylation events at LINE-1 loci in
TGCT are supported by the findings of Ferreira et al. [43]
and Ushida et al. [56].
Our results confirm previous findings indicating that
miRNAs have a relevant role during testicular carcino-
genesis, since overexpression of the miR-371-373, miR-
302 and miR-367-3p clusters was noted in malignant
TGCT tissue [12, 57, 58]. These miRNAs are implicated
in TGCT development [13], maintenance of pluripo-
tency [59], and in cisplatin sensitivity [60]. A study using
a genetic screen of primary human cells supported this
observation and found that both miR-372-373 and miR-
302 may act as TGCT oncogenes through inhibition of
target genes such as Large Tumor Suppressor homolog 2
(LATS2) [12]. These miRNAs are all highly upregulated in
TGCT, indicating a role as oncogenes in TGCT
tumorigenesis. Also among the significantly differen-
tially expressed miRNAs are miR-200c and miR-141,
both belonging to the miR-200c/141 cluster, which has
been found to act as inhibitors of the epithelial-to-
mesenchymal transition, tumor cell invasion, and me-
tastasis in several cancers [61–63]. Counter indicative
of their role as tumor suppressors, these miRNAs were
also found to be upregulated in TGCT. However, there
are some tumor types in which upregulation of the
miR-200c/141 cluster has been observed, including
ovarian carcinoma and endometrial carcinoma [64, 65].
A limitation of the present study is the possible pres-
ence of non-piRNAs among the 25–32 nt long sequences.
Although we enrich for phosphorylated small RNAs with
a 5′-OH group in the library preparations, degraded
RNAs and other non-phosphorylated RNAs may be co-se-
quenced. Compared to using PIWI protein immunopre-
cipitation [5, 17], our method gives a broader range of
small RNAs and a somewhat higher degree of non-
targeted sequences. The strong preference for 5′U and
the large overlap with piRNABank sequences, indicate
that most of our sequences 25–32 nt in length are in-
deed piRNAs. In addition, differential expression analysis
of only the sequences overlapping with piRNABank
showed a similar expression pattern, indicating a true loss
of the piRNA pathway in TGCT.
Another possible bias in the small RNA expression
measurements is differences in RNA extraction proto-
cols [66]. Most normal samples were extracted using a
phenol-free protocol, while the TGCT sample RNA ex-
traction included a phenol step. To investigate this
weakness in our design, the small RNA profiles of the
available phenol-free (n = 9) and phenol extraction (n = 3)
of the normal samples were compared. No significant dif-
ferential expression was found between samples prepared
with the two extraction methods. Regardless, a replication
study is needed to confirm potential biomarkers.
There is a need for more sensitive biomarkers for
TGCT detection and surveillance [67]. Several of the
miR-371-373 and miR-302/367 cluster members have
shown a sufficiently strong association with TGCT
[12, 57, 58] to serve as biomarkers of TGCT. Accord-
ingly, serum levels of these miRNAs have been inves-
tigated and were found to be significantly higher in
TGCT patients than in healthy controls, as well as
display decreasing levels upon treatment [68–70].
Among the miRNAs members from these clusters, miR-
371a-3p and miR-367-3p have been considered most
promising [69, 71]. We have confirmed the association
between TGCT and high expression of the miR-371-373
and miR-302/367 clusters. Despite our findings that
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differentially expressed piRNAs and tRNA-derived small
RNAs are mostly downregulated in TGCT, they may have
potential as biological markers. More research is needed
to determine the role of these sequences in TGCT car-
cinogenesis and their potential clinical use.
Conclusions
We have documented significant changes in the small
RNA populations in normal adult testicular tissue and
TGCT samples. Most notable, our results indicate loss
of the piRNA biogenesis pathway in TGCT, independent
of histological subtype, and presence of large amounts of
tRNA-derived small RNAs in both normal testicular tis-
sue and in TGCT samples. Although crosstalk between
small RNA pathways has been suggested, our results in-
dicate independent regulation of miRNA, piRNA and
tRNA-derived sequences in TGCT. These results may
contribute to increased understanding of the functional
roles of sncRNAs and their role in human spermatogen-
esis. In addition, they indicate that sncRNAs play an im-
portant role in TGCT development and progression,
and that they may be promising candidate diagnostic
markers for TGCT.
Methods
Sample collection and handling
Testicular tissue samples were selected from two
sources; i) a series of primary TGCTs previously ana-
lyzed by Skotheim and co-workers [72], and ii) a series
of normal testicular tissue samples obtained from adult
organ transplant donors, in total 37 samples (Table 2).
Rough estimate of cryosections from the three CIS sam-
ples has previously indicated the proportion of affected
tubules to be 10 %, 50 %, and 100 % [51]. The project
has been approved by the National Committee for Med-
ical and Health Research Ethics (S-05368 and S-07453b).
Small RNA library preparation and sequencing
Total RNA extracts from all samples (isolated using phe-
nol extraction or RNeasy (Qiagen, USA)) were used for li-
brary preparation and small RNA sequencing. Small RNA
sequencing libraries were generated using the Illumina
TruSeq Small RNA Sample Preparation protocol (Illumina
Inc., San Diego, CA, USA). One microgram total RNA
was ligated to 3′- and 5′-RNA adapters, and ligation
products were reverse transcribed to generate cDNA li-
braries for each sample. Products were PCR amplified,
where unique index sequences were incorporated, before
pooling of the libraries and gel purification. The samples
were size selected on a 6 % PAGE gel, cutting from the
upper side of the 160 bp marker to the lower side of the
140 bp marker, ensuring inclusion of small RNAs in the
size rage 18–36 nucleotides. Small RNA libraries were se-
quenced single read 50 bp using an Illumina HiSeq2500
sequencer (Illumina Inc., San Diego, CA, USA). Library
construction and sequencing was performed at the Oslo
University Hospital Genomics Core Facility (http://
oslo.genomics.no),
RNA-seq data processing and expression analysis
Adaptors, short reads (<17 nt) and low quality bases
were removed using Nesoni clip v0.128 (http://www.vic
bioinformatics.com/software.nesoni.shtml). Small RNA
length distribution was calculated from the trimmed
fastq output files, and the nucleotide distribution in pos-
ition 1 and 10 were calculated (custom scripts, available
upon request). Unique sequences from each histological
subtype were used as input to visualize the probability of
each nucleotide in a weblogo (v3.3) for sequences 30
and 33 nt in length [73]. Sequences longer than 17 nt
were aligned to the human reference genome (GRCh37)
using Novoalign (V3.02.00) with settings recommended
for miRNA alignments allowing maximum one mis-
match (parameters: −r All 100 -e 100 -m -l 16 -t 30)
(www.novocraft.com).
Sequences overlapping with features such as repeatmas-
ker (includes tRNAs), exon and RefSeq tracks from the
UCSC table browser (http://genome.ucsc.edu), piRNA
clusters in piRNA bank [46], and mature miRNAs in
miRBase [74] were investigated using intersectBed from
BEDtools [75]. The piRNA Bank clusters were mainly
identified using a sliding window method from sequences
associated with PIWI proteins [5]. We assumed that a set
of overlapping sequences mapping to a genomic region is
generated from the same primary transcript [22, 23], thus
all sequences with a length between 24 and 36 nt match-
ing the human genome were merged to small RNA con-
tigs using the BEDTools option bedtools merge [75]. Gaps
up to 100 bp between sequences were allowed and contigs
built from less than 100 sequences in total were discarded.
These regions were called small RNA contigs and were
used as units for measuring differential expression. Se-
quences that mapped to the small RNA contigs, miRNAs
in miRBase v20 [74], and tRNAs were quantified using
FeatureCounts from the subread package v1.4.3 [76]. To
avoid disregarding a large proportion of piRNAs mapping
to repeat sequences, piRNAs mapping to multiple loci in
the genome were included in the analysis.
Differential expression between cancer and normal
samples was calculated using counts of small RNA data
from FeatureCounts and the DESeq package v1.16.0 for
the statistical environment R [77]. For miRNA differen-
tial expression, dispersion was estimated using a pooled
method, maximum sharing mode and parametric fit
type, while for the much larger small RNA contig dataset
a pooled method, maximum sharing mode and a local fit
type was used. Heatmaps were produces with heatmap.2
from the qplot R package using variance stabilized count
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data and Euclidean measure to obtain distance matrix
and complete agglomeration method for clustering. Dif-
ferences between the mean of normalized counts for
miRNAs and small RNA contigs from cancer and nor-
mal samples were calculated using the nbinomTest.
qPCR validation
RNA from the same extraction used for sequencing was
also used for quantitative PCR validation. A total of 8
samples (4 normal, 2 seminomas, 1 EC, and 1 YST) were
selected and cDNA synthesis was performed on 0.2 μg
totalRNA using miScript II RT Kit (Qiagen, USA) ac-
cording to the manufacturer’s instructions. The qPCR
reactions were carried out on a Stratagene Mx3000p in-
strument using 1 ng cDNA, miScript SYBR Green PCR
kit (Qiagen, USA) and miScript primer assays (Qiagen,
USA). Sequences found to have a differential expression
(p < 10−6) in the sequencing dataset were selected for
validation. Primers for miRNA detection were ordered
from the Qiagen pre-designed miScript primer cata-
logue, whereas primers for piRNA and tRF detection
were designed using the Qiagen custom miScript primer
service (Additional file 7). RNU6B was used as endogen-
ous control. All samples were run in triplicates and the
relative expression was calculated using the equation
RQ = 2-ΔΔCT. CT values >35 were regarded as negative.
Additional files
Additional file 1: Absolute distribution of small RNA sequences in
three classes according to annotation.
Additional file 2: tRNA-derived small RNA expression in normal and
TGCT samples.
Additional file 3: Correlation between tRFs and tRNA halves in
normal and TGCT samples.
Additional file 4: Table indicating differentially expressed miRNAs
with p < 10−6 when adjusting for multiple testing with the
Benjamini-Hochberg procedure.
Additional file 5: Volcano plot indicating the relationship between
the Log2 fold change and p-values (Benjamini-Hochberg adjusted)
for all sequences overlapping with piRNABank.
Additional file 6: Table indicating the top 10 differentially
expressed piRNAs when including sequences overlapping with
piRNABank only.
Additional file 7: qPCR primer overview.
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